The problem with any combination with Zytiga today is, are they going to show the combo is better than Xtandi? They need to because the combo is going to cost more than Xtandi alone even though Xtandi is priced much higher than Zytiga.
Fair enough, but there's also the potential to combine OGX-427 with Xtandi as well. I believe OGXI has put forth such a possibility before. I think the initial combo trial was chosen with Zytiga because it was already approved (the upcoming combo trial will be an investigator-sponsored trial). Now that Xtandi is approved, hopefully there will be a combo trial of 427+Xtandi down the road.
Market Data 
Markets 
AI
